Monalizumab
Monalizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against NKG2-A/NKG2-B type II integral membrane protein.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | — | C34.90 | — | 2 | 1 | — | — | 3 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 1 | 1 | — | — | 2 |
| Squamous cell carcinoma | D002294 | — | — | 1 | 1 | 1 | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | 1 | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | — | — | 1 | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Non-muscle invasive bladder neoplasms | D000093284 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Monalizumab |
| INN | monalizumab |
| Description | Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies; narcotic agonists/antagonists (normorphine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297787 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 3ZXZ2V0588 (ChemIDplus, GSRS) |
Target
Agency Approved
KLRC1
KLRC1
Organism
Homo sapiens
Gene name
KLRC1
Gene synonyms
NKG2A
NCBI Gene ID
Protein name
NKG2-A/NKG2-B type II integral membrane protein
Protein synonyms
C-lectin type II protein, CD159 antigen-like family member A, CD159a, killer cell lectin-like receptor subfamily C, member 1, natural killer cell lectin, natural killer group protein 2, NK cell receptor A, NKG2-1/B activating NK receptor, NKG2-A/B type II integral membrane protein, NKG2-A/B-activating NK receptor
Uniprot ID
Mouse ortholog
—
—
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 845 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use